MAAT INDEX

CLAIM #22713 · EMR (EMR) · 2024Q2 earnings call · May 8, 2024 · due Sep 30, 2024

That may move yet another point as we go through the year.

Lal Karsanbhai · CEO

PENDING
graded after results covering Sep 30, 2024 are reported

In context

al seasonality of how our core business minus NATI, minus Aspen performs. Now obviously, Aspen is lumpy and that's in the underlying number. So that could mask the normal seasonality that we see. But in the core base Emerson operations, the second half to first half is up high single digits sequentially from a sales perspective. C. Stephen Tusa: And I guess, given the mix of MRO is so high today and the growth really isn't that strong, is the mix really changing that much? I mean, is the -- how much is the kind of lower-margin project stuff going to be up in the second half more than MRO, you know what I mean? Like can this change that much quarter-to-quarter? Surendralal Karsanbhai: No, Steve, it doesn't. So look, we were at 65% in 2023. In Q2, we're at 64%. So there was 1 point shift. That may move yet another point as we go through the year. But no, you're right. And the underlying strength of MRO in our process and hybrid business is still intact. And as certainly we go through the summer and approach the fall outages and STOs and turnaround opportunities, we look at, at least from this point in time, rather positively as well. So that's what's going to play into this as we go through the second half and, hence, gives us confidence also on that exit rate on orders for the year. C. Stephen Tusa: And then just one last one on NATI, I don't -- I haven't done the math on this 3Q guide. But is that down sequentially and then up sequentially in the fourth quarter? It looks to me like the revenue run rate now, at least for the second half versus 2Q, is basically flattish at around $370 million or something like that. Is that the r

Verify independently

SEC filings for EMR · Claim quote is verbatim from the 2024Q2 earnings call.